(NASDAQ: DYAX) announced today that executive management will participate in the UBS Global Life Sciences Conference, being held September 19-20, 2012 at the Grand Hyatt in New York City. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Thursday, September 20 at 9:00 AM (ET). Mr. Christensen will provide a corporate update regarding the Company’s key value drivers – KALBITOR
and the angioedema franchise, as well as the Licensing and Funded Research Program (LFRP).
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at
. The webcast will also be available on the Dyax website for a limited period of time following the conference.
Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s lead product, ecallantide, has been approved under the brand name KALBITOR in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Dyax is commercializing KALBITOR in the United States independently, and establishing strategic collaborations to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for ecallantide, either alone or through collaborations.
Ecallantide and other compounds in Dyax’s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the Licensing and Funded Research Program (LFRP). Collectively, LFRP agreements generate significant revenue for Dyax in the form of license fees, milestone payments and/or royalties. The success of the Company’s LFRP is illustrated by the program’s advanced licensee pipeline that includes 18 candidates in clinical development. Of those candidates, three are in Phase 3 clinical trials, six are in Phase 2 and nine are in Phase 1.